

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A pharmaceutical composition for administration to a subject in need thereof comprising an anesthetically or analgesically effective amount of a NMDA receptor antagonist selected from the group consisting of: ketamine, dextromethorphan, dextrophan, dextropropoxyphene, ketobemidone, budipine, kynurenic acid, 1-hydroxy-3-aminopyrrolidin-2-one, spermine and spermidine; and from about 0.001% to about 0.2% of a benzalkonium chloride preservative in a suitable carrier, wherein the composition does not cause any significant neurotoxicity, and wherein the level of neurotoxicity is comparable to sterile water when administered.
2. - 18. (Cancelled).
19. (Currently amended) The pharmaceutical composition of claim 1 ~~4-7~~, wherein the amount of the benzalkonium chloride is from about 0.07% to about 0.14%.
20. (Currently amended) The pharmaceutical composition of claim 1 ~~4-7~~, wherein the amount of the benzalkonium chloride is about 0.002%.
21. (Original) The pharmaceutical composition of claim 1 wherein the suitable carrier is an aqueous solution selected from the group consisting of water, saline, bicarbonate, sucrose and any mixture of the above components.
22. - 39. (Cancelled).
40. (Original) The pharmaceutical composition of claim 1, wherein the subject is a mammal.
41. (Original) The pharmaceutical composition of claim 1, wherein the subject is a human.